piracetam has been researched along with Depression in 22 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the change of health related quality of life (HRQoL), anxiety and depression in adult patients in whom an adjunctive treatment with levetiracetam (LEV) was converted to a LEV monotherapy." | 7.79 | Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. ( Arnold, S; Brandt, C; Elger, CE; Hagemann, A; May, TW; Nieder, E; Pohlmann-Eden, B; Schulze-Bonhage, A; Straub, HB; Tergau, F; Witte-Bölt, K, 2013) |
| "Levetiracetam was a probable cause of depression in these 2 elderly patients." | 7.75 | Probable levetiracetam-associated depression in the elderly: two case reports. ( Bainbridge, JL; Linnebur, SA; Vande Griend, JP, 2009) |
| "Efficacy results are reported for all seizure types [intention-to-treat (ITT) population, N = 217] and subpopulations with tonic-clonic (n = 152), myoclonic (n = 121), and/or absence (n = 70) seizures at baseline." | 6.77 | Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. ( Delanty, N; Jones, J; Tonner, F, 2012) |
| "Central neuropathic pain (CNP) is a prevalent and distressing symptom in patients with multiple sclerosis (MS)." | 6.74 | Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. ( Bernardi, G; Buttari, F; Castelli, M; Centonze, D; Codecà, C; Fiore, S; Mataluni, G; Musella, A; Rossi, S, 2009) |
| "Depression was evaluated in all experimental groups using the tail suspension and sucrose preference test on days 1, 5, 10 and 15, 2 h after pentylenetetrazole challenge." | 5.46 | Adjuvant quercetin therapy for combined treatment of epilepsy and comorbid depression. ( Goel, RK; Kaur, T; Singh, T, 2017) |
| "We report a patient with partial epilepsy secondary to neonatal stroke, who developed depressive disorder as a result of levetiracetam (LEV) treatment." | 5.35 | Levetiracetam-induced depression in a 5-year-old child with partial epilepsy. ( Auvin, S; Mazarati, A; Pandit, F; Riquet, A; Tamarelle, C; Vallée, L, 2009) |
| "A double-blind, intra-individual cross-over comparison of the effect of piracetam on retrograde memory impairement as measured by the KS memory test battery was performed in connection with second and third Bi-ECT in 18 patients diagnosed as suffering from depression." | 5.04 | Does piracetam counteract the ECT-induced memory dysfunctions in depressed patients? ( Cronholm, B; Levander, SE; Mindus, P, 1975) |
| "The aim of this study was to investigate the change of health related quality of life (HRQoL), anxiety and depression in adult patients in whom an adjunctive treatment with levetiracetam (LEV) was converted to a LEV monotherapy." | 3.79 | Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. ( Arnold, S; Brandt, C; Elger, CE; Hagemann, A; May, TW; Nieder, E; Pohlmann-Eden, B; Schulze-Bonhage, A; Straub, HB; Tergau, F; Witte-Bölt, K, 2013) |
| " However, zonisamide- and carbamazepine-treated animals had IT values similar to those of controls, but only zonisamide significantly decreased absence seizure development." | 3.77 | Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. ( Citraro, R; Constanti, A; De Fazio, S; De Sarro, G; Di Paola, ED; Perrota, I; Perrotta, I; Russo, E; Scicchitano, F, 2011) |
| "Levetiracetam was a probable cause of depression in these 2 elderly patients." | 3.75 | Probable levetiracetam-associated depression in the elderly: two case reports. ( Bainbridge, JL; Linnebur, SA; Vande Griend, JP, 2009) |
| "Efficacy results are reported for all seizure types [intention-to-treat (ITT) population, N = 217] and subpopulations with tonic-clonic (n = 152), myoclonic (n = 121), and/or absence (n = 70) seizures at baseline." | 2.77 | Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. ( Delanty, N; Jones, J; Tonner, F, 2012) |
| "The levetiracetam XR treatment group showed significantly fewer consequences than did the placebo group during the maintenance period (p = 0." | 2.77 | A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. ( A Tompkins, D; Brunette, MF; Ciraulo, D; Devine, E; Falk, DE; Fertig, JB; Green, AI; Johnson, B; Kampman, K; Litten, RZ; Mattson, ME; Pettinati, H; Ransom, J; Rickman, WJ; Ryan, ML; Scott, C; Stout, R; Strain, EC; Tiouririne, NA, 2012) |
| "Central neuropathic pain (CNP) is a prevalent and distressing symptom in patients with multiple sclerosis (MS)." | 2.74 | Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. ( Bernardi, G; Buttari, F; Castelli, M; Centonze, D; Codecà, C; Fiore, S; Mataluni, G; Musella, A; Rossi, S, 2009) |
| " Daily dosage of piracetam was 7." | 2.70 | Effect of piracetam on ECT-induced cognitive disturbances: a randomized, placebo-controlled, double-blind study. ( Leung, HC; Tang, WK; Ungvari, GS, 2002) |
| "Piracetam was found to be well tolerated in this study population." | 2.66 | The effects of piracetam in children with dyslexia. ( Blank, MS; Chase, CH; Conners, CK; Di Ianni, M; Funkenstein, HH; Helfgott, E; Holmes, JM; Lougee, L; Maletta, GJ; Wilsher, CR, 1985) |
| " All patients were kept on continuous psychotropic medication for at least 3 weeks before starting the trial, and piracetam was given additionally in a fixed dosage of 2400 mg daily; the same number of identical capsules was given during the pre- and post-treatment placebo periods." | 2.65 | Biological correlates of piracetam clinical effects in psychotic patients. ( Erban, L; Hanzlicek, L; Kabes, J; Skondia, V, 1979) |
| "Lamotrigine was preferred in patients with co-morbid depression." | 2.55 | Epilepsy treatment in adults and adolescents: Expert opinion, 2016. ( Chimato, N; Frank, RD; Karceski, SC; Shih, JJ; Vargas, E; Whitlock, JB, 2017) |
| "Any type of seizure can be observed in Alzheimer's disease (AD)." | 2.53 | Treatment of epilepsy for people with Alzheimer's disease. ( Liu, J; Wang, LN; Wang, YP; Wu, LY, 2016) |
| "The number of seizure-free patients in the last 4 weeks was overall CBZ/VPA/LTG/LEV=60%/79%/67%/67%, for generalized epilepsy was CBZ/VPA/LTG/LEV=67%/89%/65%/94%, and for localization-related epilepsy was CBZ/VPA/LTG/LEV=59%/71%/67%/57%." | 1.46 | Efficacy and tolerability of anti-epileptic drugs-an internet study. ( Baker, G; Wieshmann, UC, 2017) |
| "Depression was evaluated in all experimental groups using the tail suspension and sucrose preference test on days 1, 5, 10 and 15, 2 h after pentylenetetrazole challenge." | 1.46 | Adjuvant quercetin therapy for combined treatment of epilepsy and comorbid depression. ( Goel, RK; Kaur, T; Singh, T, 2017) |
| "Levetiracetam was independently associated with anger/aggression, nervousness/agitation, upset stomach, depression, and sleep disturbance; lamotrigine with nervousness/agitation, upset stomach, and difficulty concentrating; and valproic acid with upset stomach and shaky hands." | 1.43 | Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. ( Fidzinski, P; Gaus, V; Holtkamp, M; Kowski, AB; Losch, F; Weissinger, F, 2016) |
| "We report a patient with partial epilepsy secondary to neonatal stroke, who developed depressive disorder as a result of levetiracetam (LEV) treatment." | 1.35 | Levetiracetam-induced depression in a 5-year-old child with partial epilepsy. ( Auvin, S; Mazarati, A; Pandit, F; Riquet, A; Tamarelle, C; Vallée, L, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (22.73) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kowski, AB | 1 |
| Weissinger, F | 1 |
| Gaus, V | 1 |
| Fidzinski, P | 1 |
| Losch, F | 1 |
| Holtkamp, M | 1 |
| Wieshmann, UC | 1 |
| Baker, G | 1 |
| Liu, J | 1 |
| Wang, LN | 1 |
| Wu, LY | 1 |
| Wang, YP | 1 |
| Singh, T | 1 |
| Kaur, T | 1 |
| Goel, RK | 1 |
| Shih, JJ | 1 |
| Whitlock, JB | 1 |
| Chimato, N | 1 |
| Vargas, E | 1 |
| Karceski, SC | 1 |
| Frank, RD | 1 |
| Tamarelle, C | 1 |
| Pandit, F | 1 |
| Mazarati, A | 1 |
| Riquet, A | 1 |
| Vallée, L | 1 |
| Auvin, S | 1 |
| Rossi, S | 1 |
| Mataluni, G | 1 |
| Codecà, C | 1 |
| Fiore, S | 1 |
| Buttari, F | 1 |
| Musella, A | 1 |
| Castelli, M | 1 |
| Bernardi, G | 1 |
| Centonze, D | 1 |
| Vande Griend, JP | 1 |
| Linnebur, SA | 1 |
| Bainbridge, JL | 1 |
| Russo, E | 1 |
| Citraro, R | 1 |
| Scicchitano, F | 1 |
| De Fazio, S | 1 |
| Perrotta, I | 1 |
| Perrota, I | 1 |
| Di Paola, ED | 1 |
| Constanti, A | 1 |
| De Sarro, G | 1 |
| Delanty, N | 1 |
| Jones, J | 1 |
| Tonner, F | 1 |
| Fertig, JB | 1 |
| Ryan, ML | 1 |
| Falk, DE | 1 |
| Litten, RZ | 1 |
| Mattson, ME | 1 |
| Ransom, J | 1 |
| Rickman, WJ | 1 |
| Scott, C | 1 |
| Ciraulo, D | 1 |
| Green, AI | 1 |
| Tiouririne, NA | 1 |
| Johnson, B | 1 |
| Pettinati, H | 1 |
| Strain, EC | 1 |
| Devine, E | 1 |
| Brunette, MF | 1 |
| Kampman, K | 1 |
| A Tompkins, D | 1 |
| Stout, R | 1 |
| Hayashi, T | 1 |
| Inoue, K | 1 |
| Shinoda, J | 1 |
| Hagemann, A | 1 |
| May, TW | 1 |
| Nieder, E | 1 |
| Witte-Bölt, K | 1 |
| Pohlmann-Eden, B | 1 |
| Elger, CE | 1 |
| Tergau, F | 1 |
| Schulze-Bonhage, A | 1 |
| Straub, HB | 1 |
| Arnold, S | 1 |
| Brandt, C | 1 |
| Tang, WK | 1 |
| Ungvari, GS | 1 |
| Leung, HC | 1 |
| McGavin, CL | 1 |
| John, V | 1 |
| Musser, WS | 1 |
| Mula, M | 1 |
| Sander, JW | 1 |
| Trimble, MR | 1 |
| Ciesielski, AS | 1 |
| Samson, S | 1 |
| Steinhoff, BJ | 1 |
| Bagadia, VN | 1 |
| Gada, MT | 1 |
| Mundra, VK | 1 |
| Simon, S | 1 |
| Doshi, JM | 1 |
| Pradhan, PV | 1 |
| Shah, LP | 1 |
| Sheth, UK | 1 |
| Kabes, J | 1 |
| Erban, L | 1 |
| Hanzlicek, L | 1 |
| Skondia, V | 1 |
| Eckmann, F | 1 |
| Mindus, P | 1 |
| Cronholm, B | 1 |
| Levander, SE | 1 |
| Di Ianni, M | 1 |
| Wilsher, CR | 1 |
| Blank, MS | 1 |
| Conners, CK | 1 |
| Chase, CH | 1 |
| Funkenstein, HH | 1 |
| Helfgott, E | 1 |
| Holmes, JM | 1 |
| Lougee, L | 1 |
| Maletta, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| An Open-label, Multicenter, Follow-up Study to Evaluate the Safety and Efficacy of Levetiracetam (LEV) (Oral Tablets of 166, 250 or 500 mg b.i.d.), at Individualized Doses up to a Maximum of 4000 mg/Day (or 80 mg/kg/Day for Children and Adolescents Less T[NCT00150748] | Phase 3 | 217 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| A Phase 2, Double Blind, Placebo Controlled Trial to Assess the Efficacy Of Levetiracetam Extended Release in Very Heavy Drinkers[NCT00970814] | Phase 2 | 130 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
based on self report (NCT00970814)
Timeframe: Study Weeks 5-14
| Intervention | drinks per day (Least Squares Mean) |
|---|---|
| Sugar Pill and BBCET | 6.3 |
| Levetiracetam and BBCET | 7.1 |
A heavy drinking day is 5+ drinks per day for men and 4+ drinks per day for women based on self report. (NCT00970814)
Timeframe: Study Weeks 5-14
| Intervention | percentage of heavy drinking days (Least Squares Mean) |
|---|---|
| Sugar Pill and BBCET | 41.2 |
| Levetiracetam and BBCET | 45.8 |
A heavy drinking day is 5+ drinks per day for men and 4+ drinks per day for women based on self report. (NCT00970814)
Timeframe: Weeks 5-14
| Intervention | percentage of subjects (Number) |
|---|---|
| Sugar Pill and BBCET | 18.2 |
| Levetiracetam and BBCET | 14.1 |
2 reviews available for piracetam and Depression
| Article | Year |
|---|---|
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2016 |
Epilepsy treatment in adults and adolescents: Expert opinion, 2016.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Depression; Double-Blind Method; Dru | 2017 |
9 trials available for piracetam and Depression
| Article | Year |
|---|---|
Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study.
Topics: Adult; Analgesics; Anticonvulsants; Depression; Disability Evaluation; Female; Humans; Levetiracetam | 2009 |
Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study.
Topics: Adolescent; Adult; Anticonvulsants; Anxiety; Child; Child, Preschool; Depression; Dose-Response Rela | 2012 |
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.
Topics: Adult; Affect; Aged; Alcoholism; Anticonvulsants; Anxiety; Breath Tests; Delayed-Action Preparations | 2012 |
Effect of piracetam on ECT-induced cognitive disturbances: a randomized, placebo-controlled, double-blind study.
Topics: Adult; Depression; Double-Blind Method; Electroconvulsive Therapy; Female; Humans; Male; Memory Diso | 2002 |
A double blind trial of piracetam (UCB 6215) and placebo in cases of post-ECT cognitive deficiency.
Topics: Adult; Clinical Trials as Topic; Cognition Disorders; Depression; Electroconvulsive Therapy; Humans; | 1980 |
Biological correlates of piracetam clinical effects in psychotic patients.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adult; Depression; Drug Therapy, Combination; Energy | 1979 |
[Clinical studies with piracetam].
Topics: Age Factors; Clinical Trials as Topic; Depression; Depressive Disorder, Major; Female; Humans; Male; | 1976 |
Does piracetam counteract the ECT-induced memory dysfunctions in depressed patients?
Topics: Adult; Aged; Clinical Trials as Topic; Depression; Drug Evaluation; Electroconvulsive Therapy; Femal | 1975 |
The effects of piracetam in children with dyslexia.
Topics: Adolescent; Child; Clinical Trials as Topic; Depression; Dyslexia; Humans; Male; Memory Disorders; M | 1985 |
11 other studies available for piracetam and Depression
| Article | Year |
|---|---|
Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Depression; Drug-Related Side Effects and Adve | 2016 |
Efficacy and tolerability of anti-epileptic drugs-an internet study.
Topics: Adult; Anticonvulsants; Carbamazepine; Depression; Epilepsy; Female; Humans; Internet; Lamotrigine; | 2017 |
Adjuvant quercetin therapy for combined treatment of epilepsy and comorbid depression.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Combined Modality Therapy; Convulsants; Depressio | 2017 |
Levetiracetam-induced depression in a 5-year-old child with partial epilepsy.
Topics: Anticonvulsants; Child, Preschool; Depression; Epilepsies, Partial; Humans; Levetiracetam; Male; Pir | 2009 |
Probable levetiracetam-associated depression in the elderly: two case reports.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Depression; Epilepsies, Partial; Female; | 2009 |
Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Depression; Dose-Response Relationship, Drug; Electr | 2011 |
[Effect of levetiracetam on intractable secondarily generalized seizure and depression].
Topics: Anticonvulsants; Brain Injuries; Depression; Humans; Levetiracetam; Male; Middle Aged; Piracetam; Se | 2012 |
Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy.
Topics: Adult; Anticonvulsants; Anxiety; Depression; Drug Therapy, Combination; Epilepsy; Female; Humans; Le | 2013 |
Levetiracetam as a treatment for tardive dyskinesia: a case report.
Topics: Adrenergic alpha-Agonists; Anticonvulsants; Antidepressive Agents; Chronic Disease; Clonidine; Depre | 2003 |
The role of hippocampal sclerosis in antiepileptic drug-related depression in patients with epilepsy: a study on levetiracetam.
Topics: Adult; Anticonvulsants; Cognition Disorders; Depression; Epilepsy, Temporal Lobe; Female; Hippocampu | 2006 |
Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study.
Topics: Adult; Anticonvulsants; Anxiety; Depression; Epilepsies, Partial; Female; gamma-Aminobutyric Acid; H | 2006 |